Versus & Comparison Library
Side-by-side mechanism, half-life, dosing, and ideal-use breakdowns for every compound in our catalog. Built for researchers deep in the decision-making cycle.
| Attribute | BPC-157 | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Category | Healing & Repair | Healing & Repair |
| Mechanism | Pentadecapeptide — angiogenic, gut-protective | TB-4 fragment — actin binding, cell migration |
| Half-Life | ~4 hr (injectable) | ~2–3 days |
| Onset | 1–3 weeks | 2–4 weeks |
| Route | Subcutaneous (preferred) or oral | Subcutaneous or IM |
| Best For | Gut, tendon, ligament repair | Soft tissue, systemic repair, flexibility |
| Vial Size | 5mg | 10mg |
| Suggested BAC | 2mL | 2mL |
| Research Benefits |
|
|
Featured Comparisons
BPC-157 leads on localized gut + tendon repair with faster onset; TB-500 wins on systemic flexibility, longer half-life, and soft tissue migration. Most research stacks both — see the Wolverine protocol.
Researcher's Verdict
Stack both for joints — BPC-157 locally, TB-500 systemically.
Tirzepatide's dual GLP-1/GIP mechanism shows greater average weight reduction in head-to-head trials. Semaglutide has a longer safety record and tends to have milder GI ramp-up.
Researcher's Verdict
Tirzepatide for maximum effect; Semaglutide for gentler titration.
Retatrutide's added glucagon-receptor agonism drives meaningful additional fat oxidation and energy expenditure in research models — though Tirzepatide has more mature long-term data.
Researcher's Verdict
Retatrutide for cutting-edge research; Tirzepatide for established data.
Injectable BPC-157 delivers fast systemic distribution with high bioavailability. Oral BPC-157 is preferred specifically for upper-GI and gut-lining research where local exposure matters more than systemic levels.
Researcher's Verdict
Injectable for systemic repair, oral for GI-targeted protocols.
CJC-1295/Ipamorelin produces a clean pulsatile GH release ideal for sleep & recovery. Tesamorelin is the only GHRH analog with FDA-approved data for visceral fat reduction.
Researcher's Verdict
Tesamorelin for visceral fat; CJC/Ipa for recovery & body composition.
MOTS-c upregulates mitochondrial signaling and exercise capacity. NAD+ replenishes the coenzyme directly powering oxidative phosphorylation and sirtuin pathways.
Researcher's Verdict
Pair them — MOTS-c regulates, NAD+ fuels.
GHK-Cu alone is a focused collagen + hair signal. Glow Blend layers in BPC-157 and TB-500 for deeper dermal repair and inflammation control.
Researcher's Verdict
GHK-Cu for targeted skin signaling; Glow Blend for comprehensive remodeling.
Two peptides with similar end effects (e.g. fat loss) may work through very different pathways. Pick the one whose mechanism aligns with the research model.
Half-life determines dosing cadence. Shorter half-life = more frequent injections; longer = weekly or bi-weekly options.
Most 'vs' questions are actually 'plus' questions. The Wolverine stack (BPC + TB) and CJC/Ipa combo are case studies in synergy.
Tell us your research goal and we'll suggest the most studied compound or stack for the application.
Browse by Goal